Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesLongterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol
Journal of Rheumatology, 09/14/09
Badesch DB et al. – This study reports longterm survival rates for patients with scleroderma-associated PAH treated with IV epoprostenol. Although comparisons to historical data should be made with caution, this study reports a better survival outcome than natural history data on patients with scleroderma-associated PAH.
Methods- One hundred two patients diagnosed with PAH in association with scleroderma who received epoprostenol
- 51 PAH patients from a subject population of 56 who received epoprostenol
- 46 patients from an initial population of 55 subjects on conventional therapy who received epoprostenol in the extension study
- Open-label epoprostenol
- Adverse events, survival, and dosing information collected
- Probabilities of survival during the first and second years for all subjects who received epoprostenol during the initial randomized controlled study or during the extension study were 0.71 and 0.52
- Measure remained constant at 0.48 during the third and fourth years
Today in Autoimmune/Heritable...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögrens syndrome
Arthritis & Rheumatism, 11/06/09Vaccination, atherosclerosis and systemic lupus erythematosus
Lupus, 11/05/09Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts
Arthritis & Rheumatism, 11/11/09Today in Connective Tissue Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Nephrogenic systemic fibrosis
Current Opinion in Rheumatology, 11/04/09Effect of Sildenafil on digital ulcers in systemic sclerosis - analysis from a single centre pilot study
Annals of Rheumatic Diseases, 11/23/09Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts
Arthritis & Rheumatism, 11/11/09
Sponsor
Article Search
Sponsor